<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38624">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02061722</url>
  </required_header>
  <id_info>
    <org_study_id>PET Study in HD and HC</org_study_id>
    <nct_id>NCT02061722</nct_id>
  </id_info>
  <brief_title>[PETDE10] Imaging of PDE10A Enzyme Levels in Huntington's Disease Gene Expansion Carriers and Healthy Controls With PET.</brief_title>
  <official_title>[PETDE10] Imaging of Phosphodiesterase 10 A (PDE10A) Enzyme Levels in the Living Human Brain of Huntington´s Disease Gene Expansion Carriers and Healthy Controls With Positron Emission Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHDI Foundation, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHDI Foundation, Inc.</source>
  <oversight_info>
    <authority>Sweden: Medical Products Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to measure the availability of the PDE10A enzyme in Huntington
      disease gene expansion carriers (HDGECs) using the recently developed radioligand
      [18F]MNI-659. The study will be cross-sectional, examining HDGECs at different stages of the
      disease (pre-manifest, stage 1 and stage 2), in comparison with Healthy Controls (HCs). The
      HDGECs included in this study will be recruited from the large database of the REGISTRY
      study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>The primary outcome measure will be the distribution volume (VT) in the striatum (caudate and putamen), globus pallidus, and ventral striatum estimated using kinetic and graphical analysis. Thalamus, cortex and cerebellum will also be examined.</measure>
    <time_frame>Visit 3:  For HD subjects, this will occur within 90 days from the Screening Visit.  For Healthy Controls, this will occur within 28 days of Screening visit.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Huntington's Disease</condition>
  <arm_group>
    <arm_group_label>PET Imaging with [18F]MNI-659</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects (both HDGECs and HCs) will receive single intravenous doses of the radioligands [11C]raclopride (non-investigational medicinal product [NIMP]) and [18F]MNI-659 (investigational medicinal product [IMP]).
The radioligands [11C]raclopride and [18F]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.
The injected radioactivity of [11C]raclopride will be 300 MBq/70 kg of body weight ± 10%.
The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PET Imaging with [18F]MNI-659</intervention_name>
    <description>The radioligands [11C]raclopride and [18F]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.
The injected radioactivity of [11C]raclopride will be 300 MBq/70 kg of body weight ± 10%.
The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%.</description>
    <arm_group_label>PET Imaging with [18F]MNI-659</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capacity to give full informed consent in writing, and have read and signed the
             informed consent

          -  Age 18 to 70 years, inclusive

          -  HCs: Healthy according to medical history, physical examination, ECG, vital signs,
             laboratory assessment and MRI, with a body mass index between 19 and 27 (both
             inclusive)

          -  HDGECs: Otherwise healthy according to medical history, no co-morbidity of psychotic
             disorders, physical examination, vital signs and laboratory assessments

          -  HDGECs:

        (A) HD Stage 1 or HD Stage 2:  Patients with a clinical diagnosis of HD, defined by the
        presence of noticeable motor disorder and 40  CAG  repeats (HD stage 1: Total Functional
        Capacity (TFC) 11-13, HD stage 2: TFC 7-10); (B) Pre-manifest: Subjects that are carriers
        of the mutant Huntingtin gene with ≥40 CAG repeats, a disease burden score ≥ 275
        (calculated by the equation ((CAGn-35.5) X age)), and a Total Motor Score (TMS) ≤ 5.

          -  Able and willing to travel to Stockholm

          -  Willing to comply with use of adequate contraceptive measures:

        Exclusion Criteria:

          -  Any disease, condition or concomitant medications that significantly compromises the
             function of the body systems and that, in the opinion of the Investigator might
             interfere with the conduct of the study or the interpretation

          -  Regular use of any medication prohibited by this protocol with the exception for
             Viagra, Levitra and Cialis, which may be temporarily discontinued prior to the PET
             measurements

          -  HDGECs: History of other neurological condition (including brain surgery,
             intracranial haematoma, stroke/cerebrovascular disorders, epilepsy), co-morbidity of
             psychotic disorders

          -  HCs: Anamnesis/medical history of neurological conditions (Alzheimer´s disease,
             dementia, Parkinson´s disease, brain surgery, intracranial haematoma,
             stroke/cerebrovascular disorders, epilepsy) or psychiatric conditions schizophrenia,
             depression, bipolar disorder, attention-deficit hyperactivity disorder)

          -  HCs: Family history of HD

          -  History of or current alcohol or drug abuse or dependence

          -  History of anaphylactoid or anaphylactic reactions to any allergen including drugs
             and contrast media

          -  Haematological or biochemical parameters that are outside the normal range and are
             considered clinically significant by the Investigator

          -  Clinical relevant findings in the 12-lead ECG as determined by the evaluating
             physician

          -  Donation of blood (450 mL) within three months prior to Visit 3

          -  Contraindication to MRI, such as known claustrophobia, presence of metal devises or
             implants (e.g. pacemaker, vascular- or heart- valves, stents, clips), metal deposited
             in the body (e.g. bullets or shells), or metal grains in the eyes

          -  Participating in a clinical trial within the past 3 months

          -  HCs: previous participation in another PET study

          -  Positive viral test result for Hepatitis B or C or HIV 1 or 2

          -  Female subjects: breast-feeding or positive pregnancy test at screening or at Visit 3

          -  Contraindication for arterial cannulation (by assessment of Allen's test)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernhard Landwehrmeyer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ulm University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristina Sampaio, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CHDI Foundation, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Memory Clinic, Rigshopitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jorgen Nielsen, MD, PI</last_name>
      <phone>+45 35 45 68 01</phone>
      <email>jnielsen@sund.ku.dk</email>
    </contact>
    <investigator>
      <last_name>Jorgen Nielsen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center, Department of Neurology</name>
      <address>
        <city>Leiden</city>
        <zip>K5Q112</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verena Rodig, MSc</last_name>
      <phone>+31 715266149</phone>
      <email>v.roedig@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>R.A.C. Roos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oslo, Nevrologisk poliklinikk</name>
      <address>
        <city>Oslo</city>
        <zip>0372 Oslo</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ragnhild Wehus</last_name>
      <phone>+47 23 07 55 80</phone>
      <email>rwehus@ous-hf.no</email>
    </contact>
    <investigator>
      <last_name>Jan Frich, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skane Universitetssjukhus Lund, Neurologiska kliniken</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Reimer, RN</last_name>
      <phone>+46 46 17 41 23</phone>
      <email>jan.reimer@med.lu.se</email>
    </contact>
    <investigator>
      <last_name>Hakan Widner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhus, Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Wallden, RN</last_name>
      <phone>+46 70 627 41 40</phone>
      <email>tina.wallden-reza-soltani@karolinska.se</email>
    </contact>
    <investigator>
      <last_name>Per Svenningsson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Paucar Arce, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Knave, RN</last_name>
      <phone>+46 8 517 728 85</phone>
      <email>nina.knave@ki.se</email>
    </contact>
    <contact_backup>
      <last_name>Karin Olsson, RN</last_name>
      <phone>'+46 8 517 744 22</phone>
      <email>karin.olsson.1@ki.se</email>
    </contact_backup>
    <investigator>
      <last_name>Andrea Varrone, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrik Fazio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurologkliniken Akademiska sjukhuset, ing 85</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jimmy Sundblom, MD, PhD</last_name>
      <phone>+46 18 611 00 00</phone>
      <email>jimmy.sundblom@neuro.uu.se</email>
    </contact>
    <investigator>
      <last_name>Jimmy Sundblom, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 11, 2014</lastchanged_date>
  <firstreceived_date>February 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
